Trade Catalyst Pharmaceuticals - CPRX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023401% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001179% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 22.12 |
| Open | 22.16 |
| 1-Year Change | 43.15% |
| Day's Range | 22.16 - 22.57 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 17, 2025 | 22.46 | 0.36 | 1.63% | 22.10 | 22.58 | 22.07 |
| Apr 16, 2025 | 22.12 | -0.73 | -3.19% | 22.85 | 22.90 | 21.87 |
| Apr 15, 2025 | 23.16 | 0.67 | 2.98% | 22.49 | 23.21 | 22.46 |
| Apr 14, 2025 | 22.74 | 0.53 | 2.39% | 22.21 | 22.83 | 22.02 |
| Apr 11, 2025 | 21.99 | 0.54 | 2.52% | 21.45 | 22.08 | 20.97 |
| Apr 10, 2025 | 21.40 | -0.56 | -2.55% | 21.96 | 22.13 | 20.59 |
| Apr 9, 2025 | 22.68 | 1.83 | 8.78% | 20.85 | 23.01 | 20.34 |
| Apr 8, 2025 | 21.36 | -1.28 | -5.65% | 22.64 | 23.00 | 20.99 |
| Apr 7, 2025 | 21.75 | -0.14 | -0.64% | 21.89 | 22.85 | 20.95 |
| Apr 4, 2025 | 23.00 | -0.38 | -1.63% | 23.38 | 24.13 | 22.75 |
| Apr 3, 2025 | 24.05 | 0.57 | 2.43% | 23.48 | 24.17 | 23.20 |
| Apr 2, 2025 | 24.40 | 0.80 | 3.39% | 23.60 | 24.51 | 23.48 |
| Apr 1, 2025 | 23.85 | -0.42 | -1.73% | 24.27 | 24.41 | 23.69 |
| Mar 31, 2025 | 24.20 | -0.02 | -0.08% | 24.22 | 24.42 | 23.47 |
| Mar 28, 2025 | 24.62 | -0.23 | -0.93% | 24.85 | 24.88 | 24.20 |
| Mar 27, 2025 | 24.78 | -0.18 | -0.72% | 24.96 | 25.22 | 24.56 |
| Mar 26, 2025 | 25.09 | -0.61 | -2.37% | 25.70 | 25.82 | 24.96 |
| Mar 25, 2025 | 25.66 | -0.04 | -0.16% | 25.70 | 25.93 | 25.36 |
| Mar 24, 2025 | 25.68 | 1.11 | 4.52% | 24.57 | 26.07 | 24.54 |
| Mar 21, 2025 | 24.16 | 1.02 | 4.41% | 23.14 | 24.41 | 23.13 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Catalyst Pharmaceuticals Company profile
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company. The Company is focused on in-licensing, developing, and commercializing medicines for patients living with rare diseases. The Company is developing a pipeline of medicines for other rare diseases. The Company's product Firdapse Tablet, 10 mg, is used for the treatment of adults with Lambert-Eaton Myasthenic Syndrome (LEMS) patients (ages 17 and above) in the United States and Canada. Firdapse consists of the phosphate salt of amifampridine. It is developing a long-acting formulation of amifampridine phosphate. The Company's Firdapse is also developing clinical trials for the treatment of muscle-specific receptor tyrosine kinase-positive myasthenia gravis (MuSK-MG). Catalyst Pharmaceuticals Ireland, Ltd. is the subsidiary of the Company.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Catalyst Pharmaceuticals Inc revenues increased 18% to $140.8M. Net income decreased 47% to $39.5M. Revenues reflect Revenues increase of 16% to $138M. Net income was offset by Selling, general and adminis - Balancing increase of 14% to $45.2M (expense), reasear increase of 3% to $15.3M (expense), Other income, net decrease of 52% to $282K (income).
Equity composition
Common Stock $.001 Par, 4/11, 100M auth., 21,654,680 issd. Insiders own 22.54%. IPO 8/11/06, 3,350,000 shares @ $6 per share by First Albany Capital Inc. and Stifel, Nicolaus & Company, Incorporated. 9/08, P.O of 1.5M shares.
| Industry: | Biopharmaceuticals |
355 Alhambra Circle
Suite 801
CORAL GABLES
FLORIDA 33134
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com